Fraser Institute News Release: Canadians wait more than 450 days longer for access to new medicines than Americans and Europeans
VANCOUVER, British Columbia, May 13, 2021 (GLOBE NEWSWIRE) -- Canadian patients are waiting, on average, more than 450 days longer than Americans and Europeans to access new, potentially life-saving drugs, finds a new study released today by the Fraser Institute, an independent, non-partisan, Canadian public policy think-tank.
“Innovative new medicines can have a profound impact on the health and wellbeing of those suffering from illness. Unfortunately, Canadians are often denied these benefits for months, if not years, waiting for government to approve drugs already deemed safe and effective by regulators in the European Union and United States,” said Bacchus Barua, Associate Director of Health Policy Studies at the Fraser Institute and author of Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union.
The study finds that of the 218 drugs approved in both Canada and the United States between 2012/13 and 2018/19, approval was granted an average of 469 days earlier in the United States.
And of the 205 drugs approved in both Canada and Europe during the same period, approval was granted an average of 468 days earlier in Europe.
The main reason for this delay stems from differences in the dates on which manufacturers submitted new drugs to Health Canada for approval.
The resulting lag suggests drug companies are reluctant to launch new drugs in Canada because of a number of factors that range from Canada’s smaller market size, weaker intellectual property protections, and the federal government’s strict pricing policies.
“In some cases, pharmaceutical companies will wait up to a year after a drug has been approved in the U.S. or Europe before submitting that same drug for approval in Canada,” Barua said.
The study suggests that had Canada agreed to recognize the approval of new drugs by comparable international agencies, patients could have received access to 223 new pharmaceutical therapies (of the 224 in our sample) a median 383 (average 742) days earlier.
“Canada’s current approach, which duplicates approval processes undertaken in the U.S. and Europe, imposes considerable delays on Canadians struggling with illness. In the absence of international agreements to recognize drug approvals, policymakers should carefully consider how Canada’s drug policies attract or discourage drug companies from entering the Canadian market.”
4 Natural Ways to Ease Muscle Soreness After a Workout
After a great work out you may find yourself rewarded with sore muscles. Keep in mind that your muscles are just protein fibers that sustain intended damage during training. The goal should be to bring down the inflammation this process has caused. Instead of letting the cramps and soreness delay, next workout try a few natural remedies to keep your muscles strong and healthy.
Magnesium Supplements
Magnesium should be the go-to post-workout solution. When the body doesn’t have enough magnesium, the calcium then builds up causing cramps and spasms. Magnesium can be taken as a supplement or eat magnesium-rich foods post-workout like almonds, spinach, and cocoa. Epsom salt is a great place to start the healing journey, a warm bath with a cup of Epsom salt will help the muscles gather the magnesium out of the salty water. Be sure to check with your doctor if you take prescription medications before supplementing with magnesium.
Apple Cider Vinegar Drinks
Apple cider vinegar is both anti-inflammatory and alkalizing. Just what sore muscles need something to help reduce the inflammation. A teaspoon is all that is needed to start the muscle recovery process, it can be added to a cup of water if needed. It is also effective if applied topically.
CBD Cream
Sometimes muscle recovery needs a helping hand. A great solution is a 2000mg CBD joint pain cream. All you have to do is massage the affected area with the CBD cream and in about ten minutes the soreness will disappear. The skin absorbs the CBD, it is a powerful medicine (no prescription is needed). However, the CBD does not enter the bloodstream. It is more effective than the old sports menthols rubs that most folks are familiar with.
Turmeric Supplements
Internal support of reducing inflammation can be supplemented with turmeric. A 500mg capsule is all you need to help the body reduce inflammation after a workout. Turmeric is the ingredient in curry that gives it that yellow color and distinct flavor. It is not that exotic, turmeric capsules are readily available at drug stores and grocery stores. There are no side effects and it won’t put a taste in your mouth.
After a workout, there is no need to suffer from the pain and cramps of sore muscles. The four ingredients; magnesium, apple cider vinegar, CBD cream, and turmeric when used together treat muscles inside and outside. Natural remedies are safe to use. Together they provide a speedy recovery and no interruption in the workout schedule.
Tap into Trauma’s Emotional Energy and Use it to Power a Fulfilling Future
Los Angeles, CA, May 12, 2021 — Trauma doesn’t have to lead to a lifetime of weakness or hardship. In fact, trauma can lead to greater resilience and higher levels of achievement than we thought possible.
Dr. Randall Bell, widely considered the world’s top authority in the field of post-traumatic thriving, shares a process for not only surviving trauma but also thriving in the aftermath in his latest book, Post-Traumatic Thriving: The Art, Science, & Stories of Resilience.
“It can’t happen to me” is one of life’s greatest lies, he notes. But if or when it does happen, it’s possible to harness the emotional energy generated by the traumatic event — whether it was losing a loved one, surviving a natural disaster or being a victim of violence — and use it to heal and grow in entirely new directions.
“How do you take that energy from the trauma and tap into it to do something really remarkable that you wouldn’t have done otherwise?” asks Dr. Bell.
In Post-Traumatic Thriving, he shares stories of real people (many of them, like Leo Fender, are familiar) who have done exactly that, including:
• A deaf man with a glass eye invented the electric guitar and became a household name, remarkably wealthy and most importantly, happy.
• A convicted murderer took responsibility for the damage he caused, graduated with honors from college, became a minister and turned around the hearts of the most hardened criminals.
• A girl born with cerebral palsy landed the world’s first starring role on national television and spoke at the White House three times.
• A woman hid in a basement for years and lost her entire family in the Holocaust. She eventually found true love and paints stunning artwork.
• The sister of a murder victim helped millions of women in toxic domestic relationships.
• A woman’s car crash resulted in an addiction to prescription drugs, a divorce, a loss of her children and a cot in a homeless shelter. She has rebuilt it all back and more.
• A man set to go to the Olympics had his hopes dashed by Jimmy Carter and went on to build a worldwide business empire.
Dr. Bell juxtaposes outcomes of scientific studies with these stories to reveal common denominators among “thrivers.” He divides his insights into three sections: The Dive Stage, The Survive Stage and The Thrive Stage, and outlines a step-by-step process toward authentic healing.
As a socio-economist, Dr. Randall Bell has consulted on more disasters on earth than anyone in history. His clients include the Federal Government, State Governments, International Tribunals, major corporations and homeowners. Dr. Bell believes that “the problem is not the problem — the problem is how we react to the problem.”
Often called the “Master of Disaster,” Dr. Bell is squarely focused on authentic recovery and resilience. His research has been profiled on major television shows and featured in numerous magazines and the international media. More information can be found at www.posttraumaticthriving.com.
Post-Traumatic Thriving: The Art, Science, & Stories of Resilience
Ontario "not ready yet" to end lockdown, doctors say
TORONTO, May 12, 2021 /CNW/ - Ontario's doctors support the government extending the province-wide pandemic lockdown due to expire May 20 and recommend easing restrictions on outdoor recreation where it is safe to do so.
The Ontario Medical Association says the province is not yet ready to lift the stay-at-home order while about 2,000 people are testing positive for COVID-19 every day and 1,800 people are so sick they need hospital care, 800 of them in intensive care units.
But doctors do prescribe reopening more outdoor recreational facilities such as golf courses and basketball and tennis courts to improve people's physical and mental health. This needs to be done safely and with clear guidelines around when to wear masks and how many people can gather to avoid large COVID-spreading events on the May 24 long weekend.
"We all want the third wave to be the last wave," said OMA President Dr. Samantha Hill. "We're just not ready yet to reopen. No one wants to start lifting restrictions too soon, only to find the virus spreading again and we have to go back into lockdown."
Extending the stay-at-home order significantly increases the likelihood Ontarians can enjoy a less restrictive summer and have a "more normal" fall.
The OMA calls on all Ontarians to continue following public health guidelines to ensure the third wave is the last wave of the pandemic. The most important thing everyone can do is get vaccinated and talk to their family doctor or local public health unit if they have any questions.
The OMA said how long the lockdown needs to be extended depends on many factors, including how many people are vaccinated and when. But the decision should be based on evidence and advice from the province's COVID-19 Science Advisory Table. Even when we do start to reopen safely, it will take weeks, and in some cases, months, for some of those numbers to fall significantly.
While care in the community should open soon, we need to ensure hospitals have capacity to care for people who continue to be infected with the virus as well as non-COVID patients. Intensive care units continue to be over capacity. Doctors, nurses and other health-care workers who have been working on the front lines of the pandemic for more than a year also are in need of breaks to tend to their own physical and mental health.
"People are tired of restrictions being lifted only to be put in place again a few weeks later," said OMA CEO Allan O'Dette. "It is hard on the economy and hard on people's livelihoods and mental health. Please get vaccinated as soon as possible, keep maintaining physical distancing and exercise good hygiene."
The OMA is holding a media briefing today (May 12) from 1-2 p.m. to discuss these recommendations. Journalists can register here.
For more information, please contact: OMA Media Relations at media@oma.org
About the OMA
The Ontario Medical Association represents Ontario's 43,000-plus physicians, medical students and retired physicians, advocating for and supporting doctors while strengthening the leadership role of doctors in caring for patients. Our vision is to be the trusted voice in transforming Ontario's health-care system.
SOURCE Ontario Medical Association
Real Treat Becomes First Canadian Brand and First Organic Product to Win the Prestigious Gold SOFI Award in its Category
COCHRANE, Alberta, May 12, 2021 (GLOBE NEWSWIRE) -- Organic cookies can still be swoon-worthy as Real Treat has proven with its Lemon Sablés with Herbes de Provence that have been awarded Gold in the Cookies & Sweet Snacks category of the Specialty Food Association’s 2021 sofi™ Awards. This award marks the first time a certified organic cookie has won a sofi™ Award, and Real Treat is the first Canadian brand to win a sofi™ in this category since the inception of the sofi™ award in 1972.
To win the highly competitive sofi™ Award, Real Treat’s cookies were blind taste tested by a group of expert judges made up of seasoned food professionals including chefs, culinary instructors, recipe developers and specialty food buyers. Judges scored each submission on multiple qualities including flavour, appearance, texture, aroma and creativity. With its Gold award recognition, Real Treat outperformed all other competitors included in the category.
“The sofi™ Gold Award is the highest honour in the specialty food industry. Winning one is a tremendous achievement and a true validation of our mission to create organic cookies that are decadent and delicious,” said Jacqueline Day, Founder, Real Treat. “For too long organic treats have fallen into the category of ‘consolation prize food’ and we are here to change that.”
Real Treat launched in 2014 with its Top Shelf line of gourmet organic cookies. These are premium cookies with creative flavours having strong appeal with foodies. Unique for being both organic and epicurean, these cookies caught the attention of New York Times Food who called them, “Cookies for the Sophisticated Set.” The sofi™ winning Lemon Sablés with Herbes de Provence was among the first products to be launched from this line. Since its debut this cookie has been featured at distinguished wineries in the Napa Valley and top tier cheese boutiques due to its unique talent for pairing beautifully with wine and cheese.
Real Treat demonstrates their creativity and high standard of quality and flavour with three additional flavours in the Top Shelf line, including their wildly popular Salted Caramel Shorties with Fennel, Dark Chocolate Chunk with Smoked Pecans, and Double Dark Chocolate with a Twist cookies. Some pair with wine and cheese, while others are the ideal indulgence to enjoy with a fine single malt scotch.
For the more traditional cookie lover, Real Treat offers their Real Treat Pantry line. Also certified organic, these cookies are made with clean ingredients while satisfying the craving for cookies we grew up enjoying as children, freshly baked in our home ovens. These are the cookies of childhood tea parties and after-school snacks. Here you will find mouth-watering nostalgic favourites like Chocolate Chunk, Oatmeal Raisin, and Brown Sugar Shortbread. The Pantry line is a current finalist for a NEXTY Award. New Hope Network will announce the winner at their upcoming virtual Natural Products EXPO.
Real Treat products are available at select retailers across Canada and the United States, and online at realtreat.ca. Retailers selling Real Treat products can be found using Real Treat’s Stockist Finder.
About Real Treat
Real Treat is based in the foothills of the Rocky Mountains in beautiful Cochrane, Alberta, Canada. A wholly woman-owned business founded by Jacqueline Day in 2014, their small-batch organic cookies have a passionate following of foodies and cookie monsters big and small across North America and have been raved about in the pages of The New York Times Food, Culinaire, Gourmet News, Toronto Life and Avenue magazines.
All products in the Real Treat lineup are USDA, EU, and Canada certified organic by EcoCert.
About the Specialty Food Association The Specialty Food Association (SFA), is the leading trade association and source of information about the $158.4 billion specialty food industry. Founded in 1952 in New York City, the SFA represents makers, importers, retailers, distributors, and others in the trade. The SFA is known for its Fancy Food Shows; the sofi™ Awards, which honor excellence in specialty food and beverage; Trendspotter Panel Show reports and annual predictions; the State of the Specialty Food Industry Report; the Product Marketplace database, featuring specialty foods and beverages in 161 categories and sub-categories; Infinite Aisle, a new ecommerce marketplace that enables SFA Members to make buyer-maker connections and sales year-round; and Specialty Food LIVE!™, a digital marketplace experience.
Memoir Details Author’s Journey with Mental Illness and Disability Long Island, NY, May 12, 2021 – As we enter Mental Health Awareness month, one author and artist is sharing her coming-of-age story through the lenses of mental illness, disability and steadfast determination. Long Island native Ruth Poniarski’s first book, Journey of the Self: Memoir of an Artist, published by Charlotte, North Carolina-based Warren Publishing, is a stunning and unflinchingly-honest memoir that challenges the stigmas placed on mental illness. The book has received glowing reviews, including a Kirkus Star review.
It started as a college prank; a friend offered Ruth Poniarski a brownie that, unbeknownst to her, was laced with angel dust. What resulted was a debilitating accident, and the first of many mental breakdowns that spiraled into diagnoses of psychosis, schizophrenia, severe anxiety and bipolar disorder.
For years, Poniarski struggled to cope with her new reality as she undertook a rigorous architectural program, sought out new friends (and the perfect mate) and battled through the depths of mental illness. Her journey led her in all directions as she sought comfort, solace, stability and love.
Now an accomplished artist, Poniarski considers her memoir to be a portrait of sorts.
“This book, like many of my paintings, is about introspection,” she says. “So many of us, particularly when we’re young, seek definition through labels or through what others think of us. It’s so easy to say, ‘I have bipolar disorder, therefore, X,’ or, ‘So and so doesn’t love me the way I love him, therefore, Y.’ But none of that is who we truly are.”
The release of Poniarski’s memoir is particularly timely in light of the coronavirus pandemic and social distancing orders.
“A lot of people are stuck at home right now. This kind of isolation forces a person to examine themselves; what makes them unique beyond who they are to society,” says Poniarski. “That kind of self-reflection allows us to become more available to others. You have to know yourself first.
“So, who am I?” Poniarski laughs. “Well … you’ll just have to read the book!”
For more information about Ruth Poniarski or her book, please visit: ruthponiarski.com.
CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences
MONTREAL, May 11, 2021 /CNW Telbec/ - CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ("Reveal"), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta's position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications.
Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research, clinical trials, and improve patient outcomes globally. Reveal's imageDx™ pathology platform combines cutting edge machine learning (ML)-AI with traditional histopathology to transform tissue biology into actionable data. Reveal's unique proprietary pipeline architecture and biomarker-based training methods also enable the development of scalable custom AI models for specific pathology endpoints, companion diagnostics and predictive models integrating multi-omic data.
"Reveal's exceptional AI and machine learning capabilities will support more objective tissue biomarker quantitation and will enable a broader and faster deployment of our histological services," said Martin LeBlanc, CEO of CellCarta. "Acquiring this leading business is part of a game-changing strategy to expand our services to better support our global clients who are actively seeking more objective, reproducible and scalable methods for tissue biomarker assessment, deployed within a robust quality and regulatory platform."
"We are excited to join forces with CellCarta," said Claire Weston, PhD, CEO and Co-Founder of Reveal. "Reveal's broad portfolio of automated digital assays target Oncology, NASH, Neuroscience, Fibrosis, Inflammation and other therapeutic areas. We see great opportunity in combining these AI capabilities with CellCarta driving towards better diagnoses and more meaningful clinical trials on a global scale."
About CellCarta CellCarta is a leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials. The company operates globally with 10 facilities located in Canada, USA, Belgium, Australia, and China.
About Reveal Biosciences Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research and improve patient outcomes globally. Reveal's imageDx™ pathology platform provides AI data analytics and cloud-based whole slide image management to Life Sciences and Healthcare. With a world class team of data and research scientists focused on addressing some of the biggest problems in healthcare, Reveal has developed a pipeline of AI-based digital assays for preclinical research, clinical trials, and diagnostics.
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2021 Financial Results on Monday May 17, 2021
BEVERLY HILLS, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.®(“TOMI”) (Nasdaq:TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced it will report results for the first quarter ended March 31, 2021 after the close of the financial markets on Monday, May 17, 2021 and will hold a conference call at 4:30 p.m. ET that day.
To participate in the call by phone, dial (877) 545-0320 and entry code 408875 approximately five minutes prior to the scheduled start time. International callers please dial (973) 528-0016 and use entry code 408875. To access the live webcast or view the press release, please visit the Investor Relations section of the TOMI website at: http://investor.tomimist.com/TOMZ/webcasts_and_events/2145
A replay of the teleconference will be available until May 28, 2021 and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use replay access code: 41341. A replay of the webcast will be available for at least 90 days on the company’s website, starting approximately one hour after the completion of the call.
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
I
Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, have met another early milestone in the development of an initial all natural psilocybin extract.
Optimi and Numinus, through Impact Clinical Trials Accelerator at the University of Calgary (“Impact”), have submitted a pre-clinical trial application to Health Canada for review and comment. Meanwhile, cultivation, research, formulation, and continuous validation studies to produce the investigational psilocybin extract for trial continue at the Health Canada-licensed Numinus lab in British Columbia, Canada.
Key information submitted in the information package provided to Health Canada includes the investigational product’s chemical constituents, genotype, and formulation as well as procedures and processes to produce a consistent dosage from Psilocybe mushrooms.
With Health Canada’s feedback and anticipated regulatory approvals, Numinus plans to use the candidate mushroom clone to develop a uniform all-natural psilocybin capsule for use in Optimi’s human clinical trials, initially for a dosing study and then expanding into trials for a variety of human health conditions.
Optimi will retain 100% ownership of the resulting all-natural psilocybin capsule and full intellectual property rights to its use.
Optimi Chairman of the Board JJ Wilson comments, “This is another important step for our commitment to the development of naturally sourced, evidence-based product formulations. As a cornerstone of our brand positioning, we believe that future consumer demand will be based on efficacy, cost, and source integrity. By using natural products, we seek to unlock the full value potential in this sector. With the work we are embarking on today with the teams at Numinus and Impact, we are aiming for what we hope will become blockbuster candidates able to significantly transform the mental health therapeutic landscape, while remaining true to historic principles and natural organic origins.”
“Numinus is pleased to partner with Optimi on this important work and provide the expertise, licensed facility and specialized equipment required to quickly develop, formulate and rigorously test products derived from natural Psilocybe sources and prepare them for Health Canada submissions and approvals,” said Sharan Sidhu, Science Officer and General Manager, Numinus Bioscience. “We look forward to continuing our work with Optimi to develop safe, standardized and reproducible products that provide meaningful and accurate clinical trial data.”
Numinus Bioscience recently received amendments to its federal license to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including – for the first time – Ketamine and Lysergic acid diethylamide (LSD). The amendment also supports Numinus Bioscience’s role in activities related to Mescaline, N, N-Dimethyltryptamine (DMT), N-Methyl 3,4, methylenedioxyamphetamine (MDMA), Psilocin and Psilocybin.
ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.
ABOUT NUMINUS WELLNESS Numinus Wellness (TSX-V; NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.
FORWARD‐LOOKING STATEMENTS This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, "forward‐looking statements") that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements" and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Nabati Foods Completes Construction of Expanded Manufacturing Facility
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Nabati Foods Global Inc. (CSE: MEAL Reserved) (“Nabati Foods” or the “Company”), a plant-based food tech company offering whole, natural, plant-based foods for health-conscious consumers, is announcing that it has completed the construction of a brand new manufacturing facility. The new production facility in Edmonton, Alberta is five times larger than The Company's pilot facility and will serve to support the company's continued growth.
The construction of this capital asset follows the completion of Nabati Foods’ successful oversubscribed financing of $7.7 million and positions it to fulfill wholesale orders and support its growth in the U.S. as well as support market entry into the EU.
“There has been enormous demand for our products from across North America from all of our customer categories including grocery, foodservice, and industrial,” Nabati CEO Ahmad Yehya said. “By significantly increasing our production capacity, we will be in a strong position to capitalize on growing customer demand.”
The extra square footage will enable the Company to house its full research and development (R&D) department and expand its team 150 percent to 15 members with room to grow the team further. In addition, the facility will be able to simultaneously produce 1.2 million pounds of plant-based cheeze and 1 million pounds of plant-based meat, with room to expand capacity further. This additional R&D capacity will also give Nabati the ability to put additional resources into product development.
“Beyond just meeting demand, it is important to us to keep innovating, and this additional capacity will make that possible,” Yehya said. “Our product line is set to continue to expand with great innovations coming very soon. For example, we plan to begin production of Nabati Cheeze slices at the new facility by fall 2021, which for which we have a long waiting list for from foodservice clients.”
Nabati Foods products are served across North America. All Nabati products are gluten-free, kosher, vegan, and non-GMO.
About Nabati foods Inc. Nabati Foods Global Inc. is the owner of Nabati Foods Inc. (“Nabati”), a family-founded food tech company offering whole, natural, plant-based, gluten, and soy-free foods for health-conscious consumers. Nabati was founded in 2014 and has four signature product lines including dairy-free cheesecakes, cheese alternatives, and plant-based meats. Nabati products are distributed in Canada and the U.S. through grocery, foodservice, and industrial channels. Learn more: https://invest.nabatifoods.com/
For further information, please contact : Ahmad Yehya at ir@nabatifoods.com
Disclosure and Caution
Completion of the financing is subject to a number of conditions, including ensuring the financing and listing application are compliant with CSE requirements. The transaction cannot close until the required conditions are satisfied and required approvals are obtained. There can be no assurance that the financing will be completed as proposed or at all. Trading in the securities of the Company should be considered highly speculative – there is no active market for Company’s securities at this time. No regulatory body has reviewed or approved the terms to this financing.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the ability to complete the financing, the ability to satisfy the conditions required and approvals needed to complete the transaction, availability of funds and the results of financing efforts, - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States unless pursuant to an exemption therefrom. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
